Clinical trial DESTINY-PAN01
A Phase II, multicenter, open-label study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology
| Organ | Multiple |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2020-002368-30 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04639219 |
| Last update |